Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Other Non Operating Income (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Other Non Operating Income for 11 consecutive years, with -$12.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income fell 1427.75% year-over-year to -$12.5 million, compared with a TTM value of $29.5 million through Dec 2025, up 242.22%, and an annual FY2025 reading of $29.5 million, up 242.22% over the prior year.
  • Other Non Operating Income was -$12.5 million for Q4 2025 at Spyre Therapeutics, down from $40.3 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $40.3 million in Q3 2025 and bottomed at -$21.4 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is -$525650.0, with a median of -$30500.0 recorded in 2021.
  • Peak annual rise in Other Non Operating Income hit 9658.33% in 2023, while the deepest fall reached 356433.33% in 2023.
  • Year by year, Other Non Operating Income stood at -$15000.0 in 2021, then surged by 60.0% to -$6000.0 in 2022, then tumbled by 356433.33% to -$21.4 million in 2023, then skyrocketed by 96.18% to -$818000.0 in 2024, then tumbled by 1427.75% to -$12.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for SYRE at -$12.5 million in Q4 2025, $40.3 million in Q3 2025, and -$656000.0 in Q2 2025.